# Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects

> **NCT05158335** · PHASE1 · COMPLETED · sponsor: **MBX Biosciences** · enrollment: 76 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MBX 2109 (Part A)
- **DRUG:** MBX 2109 (Part B)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05158335
- **Lead sponsor:** MBX Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-10
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-06-20
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05158335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05158335, "Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05158335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*